AstraZeneca Shrugs Off COVID Antibody’s Inferiority In Therapy Setting, Sees Prevention As Main Role

Injection Cut Risk By 50%

 
• By Andrew McConaghie
  
AstraZeneca biologics
AstraZeneca's 600mg intramuscular dose is much lower than rival IV therapies, which should make hitting production easier, but the company is not disclosing its manufacturing targets.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip